Observational data suggest that the use of bilateral internal mammary arteries (BIMA) during coronary artery bypass graft surgery provides superior revascularization to a single internal mammary artery (SIMA), but concerns about safety have prevented the widespread use of BIMA. The Arterial Revascularisation Trial (ART) is a randomized trial of BIMA vs. SIMA, with a primary outcome of survival at 10 years. This paper reports mortality, morbidity, and resource use data at 1 year.
Introduction
Despite advances in percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) surgery remains the best therapy, prognostically and symptomatically, for severe multivessel ischaemic heart disease. 1 -3 Consequently, CABG remains one of the most commonly performed operations worldwide. Most CABG patients require three bypass grafts (one to each of the major coronary arteries), and from the inception of CABG in the 1960s, the most commonly used conduit was saphenous vein.
In 1986, however, when the Cleveland Clinic group reported 4 that a single internal mammary artery (SIMA) rather than vein graft to the left anterior descending (LAD) coronary artery (anatomically, the most important coronary artery) improved 10-year survival and freedom from recurrent angina, myocardial infarction, and the need for repeat intervention, the use of a SIMA graft rapidly became the 'gold standard'. Indeed, more than 95% of the CABG patients currently receive a SIMA graft and its benefits of excellent long-term patency in comparison with vein grafts are now known to extend into the second and third decade of follow-up. 5, 6 That superior clinical outcome is largely due to the excellent long-term patency of a SIMA graft, with rates in excess of 90% up to a decade after CABG, in contrast to vein grafts where, due to atherosclerosis, around half are occluded and half of the remainder are severely diseased. 7 -9 The superior clinical outcome associated with a SIMA graft encouraged several groups to investigate the use of bilateral internal mammary arteries (BIMA) with reports of even better clinical outcomes. 10 -14 Angiographic studies demonstrate markedly superior patency of BIMA grafts compared with vein grafts, with patency rates of BIMA grafts being as high as 98% at 7 days 15 and 95% at 2 16 Although BIMA grafting appears to offer superior revascularization to SIMA, it is technically more challenging, and concerns that it leads to a longer operation and increases the risk of early mortality and major morbidity, in particular impaired wound healing, 6, 12, 13 have prevented widespread use. Indeed, BIMA grafting is only used routinely in around 10% of the CABG patients in Europe 18 and 4% of the CABG patients in the USA. 19 The primary objective of the Arterial Revascularisation Trial (ART) is to assess whether the use of BIMA grafts during CABG improves 10-year survival and reduces the need for further interventions compared with a SIMA graft. The secondary outcome measures include clinical events and quality of life (QoL) and health economic assessments. However, because of concerns over the 'safety' of the routine use of BIMA grafts, 6, 12, 13, 20, 21 the results presented in this paper describe the mortality and morbidity data up to 1-year post-randomization.
Methods

Trial design
The protocol for ART has been published. 22 Briefly, ART is a two-arm, randomized multicentre trial, conducted in 28 hospitals in seven countries, with patients being randomized equally to SIMA or BIMA grafts. All eligible patients requiring CABG were considered for entry into the study. Eligible patients were those with multivessel coronary artery disease (including urgent patients but not evolving myocardial infarction) undergoing CABG, whereas those requiring single grafts or redo CABG were excluded. The ART study complied with the Declaration of Helsinki. The trial commenced after ethical approval was obtained in participating centres and each patient was required to provide written informed consent. Central co-ordination for the study was provided by the Clinical Trials and Evaluation Unit (CTEU) at the Royal Brompton and Harefield NHS Foundation Trust in London and the study was sponsored by the University of Oxford.
The randomization sequence was generated with randomly varying block sizes and stratified by centre, 23 to provide equal numbers in each group. Patients were enrolled and randomized by telephone call to the co-ordinating centre. To reduce the possibility of outcome events occurring between randomization and revascularization, it was recommended that surgery be performed within 6 weeks of randomization.
Surgical procedure
The SIMA group received a SIMA graft to the LAD plus supplemental vein or radial artery graft to other coronary arteries, whereas the BIMA group received BIMA grafts to the two most important left-sided coronary arteries with supplemental vein or radial artery to other coronary arteries. In the BIMA group, the internal mammary artery (IMA) grafts could be used as composite grafts to each other, as long as one remained in situ. Anastomosis of an IMA graft to the right coronary artery was not permitted because of concerns of inferior long-term patency. Only surgeons with experience of .50 BIMA operations were able to undertake BIMA procedures in the trial and standard methods for anaesthesia and myocardial protection were used according to local practice.
Outcome measures
The primary outcome of ART is a comparison of all-cause mortality at 10 years of follow-up between patients randomized to the SIMA or BIMA procedure. The main outcomes in this analysis were clinical outcomes at 30 days and 1 year (all-cause mortality, myocardial infarction, stroke, and repeat revascularization) and safety outcomes including sternal wound reconstruction. Data were censored as of 1 July 2010. Serious adverse events were reported by the investigators on specific forms. Two members of the Clinical Event Review Committee (membership given in Appendix) then adjudicated each event (death, myocardial infarction, stroke, and re-intervention) in a blinded fashion to ensure that the events met the definitions given. If the two adjudicators did not concur, then the event was adjudicated by a third adjudicator. All other adverse events requiring or prolonging hospitalization were adjudicated by one member of the Committee. Patient's QoL was assessed using the shortened WHO Rose angina questionnaire 24 and the EuroQol EQ-5D questionnaire. 25 
Trial size
To detect a true absolute 5% reduction in 10-year mortality (i.e. from 25 -20%), with 90% power at 5% significance level required 2928 patients. The aim was to enrol at least 3000 patients (1500 in each arm) over a 2-to 3-year recruitment period.
Statistical analysis
The trial data were analysed by intention-to-treat, irrespective of actual management and events. The Kaplan-Meier method was used to analyse time to death. The number and percentage of events at 30 days and 1 year were calculated by treatment groups. We calculated the relative risks and corresponding 95% CI to describe the direction and magnitude of the treatment effect. All analyses were performed using Stata software version 11 (StataCorp). Health resource use data were presented as medians and also as Figure 1 shows the flow of participants through the trial. Screening logs completed by each centre showed that 28% of the patients who met the eligibility criteria were actually randomized into the study.
One thousand five hundred and fifty-four patients were randomized to SIMA and 1548 to BIMA. The groups were well matched with respect to age, gender, ethnic origin, body mass index, systolic and diastolic blood pressure, and smoking status ( Table 1) . The groups were also well matched for co-morbidities including diabetes ( 6% insulin-dependent and 18% non-insulin-dependent), previous stroke or transient ischaemic attacks, and peripheral vascular disease. Both groups had similar severities of angina and breathlessness and a similar incidence of previous myocardial infarction and/or PCI with stenting. Approximately 8% of the patients had unstable angina. Table 2 shows the surgical details for each group. Approximately 97% of the patients in each group had their surgery within 6 weeks of randomization. The mean number of grafts in both groups was 
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Randomized trial to compare BIMA vs. SIMA 3. In the SIMA group, 96.6% received a SIMA graft, whereas 3.4% did not. In the BIMA group, 84.5% received BIMA grafts, whereas 15.5% did not. The reasons reported by the investigator for the patient not having the allocated procedure at surgery were: for patients allocated SIMA: vessel unsuitable due to size or condition (n ¼ 15, 29%), patient status (n ¼ 5, 10%), surgeon preference (n ¼ 16, 31%), unsuitable coronary anatomy (n ¼ 12, 23%), or other reason (n ¼ 4, 7%); and for patients allocated BIMA: vessel unsuitable due to size or condition (n ¼ 72, 30%), patient status (n ¼ 60, 25%), surgeon preference (n ¼ 54, 23%), unsuitable coronary anatomy (n ¼ 42, 18%), or other reason (n ¼ 9, 4%).
Forty per cent of procedures in the SIMA group and 42% in the BIMA group were done off-pump. The mean (SD) operation time was 199 min (58) for SIMA and 222 min (61) for BIMA (mean difference 23 min, 95% CI: 19 -27). In the immediate postoperative period, 4% of the patients were returned to the operating room predominantly because of bleeding. The use of blood products was similar in both groups. Approximately 4% of the patients required an intra-aortic balloon pump and the respective use of renal support was 4.4 and 5.9%. The mean duration of ventilation was 863 min in the SIMA group and an additional 105 min in the BIMA group. For patients admitted to ITU following surgery, the mean (SD) length of stay was 38 h (106) in the SIMA group and 41 h (94) in the BIMA group (mean difference 3 h, 95% CI: 25 to 10). The mean (SD) total post-operative hospital stay was 7.5 (7.6) and 8.0 (7.4) days in the SIMA and BIMA groups, respectively (mean difference 0.5 days, 95% CI: 20.03 to 1.03 days). Table 3 shows the adverse events for each group and Figure 2 shows the time from randomization to death by the randomized group (cut-off at 12 months). For SIMA and BIMA, 30-day mortalities were 1.2 and 1.2% in each group and respective 1-year mortalities were 2.3 and 2.5% ( Table 4) . The rates of stroke and myocardial infarction and repeat revascularization were similar at 30 days and 1 year.
The incidence of sternal wound reconstruction was 0.6% for SIMA and 1.9% for BIMA, and in both groups, around half of these patients had a history of diabetes in comparison with around one-quarter of all patients in the whole trial. There was little difference between the BIMA and SIMA groups in QoL at 12 months as measured using the shortened WHO Rose angina questionnaire or the EuroQol EQ-5D ( Table 5) .
Discussion
The ART is unique in not only being the largest randomized trial of two surgical operations ever undertaken in cardiac surgery but also with a primary outcome at 10 years of follow-up. It is designed to specifically answer the question of whether BIMA grafts offer additional survival benefit and freedom from re-intervention at 10 years to that already provided by a SIMA graft.
There are two key findings of the 1-year interim analyses of ART. The first is the overall very low mortality and major morbidity of contemporary CABG, irrespective of whether the procedure was BIMA or SIMA, with a 30-day mortality of around 1% and a 1-year mortality of around 2.5%. This is consistent with other contemporary reports of CABG outcome such as the SYNTAX Trial 3 and the United Kingdom National Database for Cardiac Surgery, 18 which reported an in-hospital mortality of around 1.1% in all 78 000 elective CABG patients in the UK for the 5-year period 2004-08. Likewise, the rates of stroke, myocardial infarction, and repeat revascularization were all ≤2% at 1 year and similar between the two groups. The use of BIMA grafts added, on average, 23 min to the duration of operation and 105 min to the duration of mechanical ventilation but did not significantly affect the duration of ITU stay or post-operative duration of hospital stay.
The second key finding is a 1.3% increase in the incidence of sternal wound reconstruction associated with the BIMA. Diabetes is a well-recognized major risk factor for impaired sternal healing and it is notable that approximately half of all patients requiring sternal reconstruction had diabetes in comparison with around onequarter of all patients in the trial as a whole. This slight increase in the risk of need for sternal reconstruction in diabetic patients has to be balanced against the fact that diabetic patients tend to have the most severe coronary artery disease and may actually be the very patients with most to gain from BIMA grafts. 27 The risk of impaired wound healing can be minimized with judicious patient selection (avoiding BIMA grafts in obese diabetic patients or those with respiratory impairment) and modification of the IMA dissection CVA, cerebrovascular accident; MI, myocardial infarction; PCI, percutaneous coronary intervention; NYHA, New York Heart Association; CCS, Canadian Cardiovascular Score.
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method whereby harvesting only the IMA ('skeletonized') rather than the IMA and its surrounding tissue ('pedicled') preserves collaterals and sternal blood supply 28, 29 and improves wound healing, particularly in diabetic patients. 30 There was no evidence of QoL differences between the BIMA and SIMA groups at 12 months.
One key issue is whether participating surgeons were appropriately experienced to conduct this trial? The trial .......... ............ ............ ............ ........... ............ ............ ............ ........... ............ ............ ............ ........... ............ .........   .. ........... ............ ............ ............ ........... ............ ............ ............ ........... ............ ............ ............ ........... ............ ....... protocol stipulated that surgeons should have performed at least 50 BIMA grafts to be eligible for participation. In the SIMA group, 3.4% did not receive their randomized treatment compared with 15.5% in the BIMA group. This higher figure for the BIMA group may in part reflect some degree of inexperience in doing BIMA operations, but about 40% of all CABG surgeries were performed 'off-pump', suggesting a high level of surgical expertise in the surgeons in this trial. This is also emphasized by the very low rate of intra-operative conversion from off-pump to on-pump CABG at 2%. One of the major strengths of ART is that it has been carried out in a broad range of centres in seven countries and includes more than a quarter of all patients who received CABG in those centres during the enrolment period. This supports the generalizability of our results to routine clinical practice. The trial stipulated that for optimal patency, both IMA should be placed to the left-sided arteries as previous studies had suggested that patency of the right IMA was lower if placed to the right coronary artery due to size discrepancy and eventual disease development at the crux. 12 More recently, the Cleveland Clinic group reported that the right IMA could be placed to either the circumflex or right coronary artery system (with at least a 70% stenosis) with similar early and late outcomes. 
Conclusion
Analysis of early data from this trial demonstrates similar surgical mortality and major morbidity for both the SIMA and the BIMA groups at 30 days and 1 year but with a small increase in the need for sternal wound reconstruction using BIMA. These results support the feasibility of CABG using BIMA grafts in patients undergoing CABG. Particular care should be used in patient selection especially in the case of diabetics. These are early data from a longterm trial, and results from 10-year follow-up will in time provide more definitive evidence on survival, morbidity, the need for repeat intervention, and the relative costs and cost-effectiveness of BIMA vs. SIMA grafting in coronary revascularization. 
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